- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01426308
Method Comparison and Clinical Specificity Study: Evaluation of the Infinium HD Cytogenetic Abnormality Test
The study will determine the performance of the Infinium HD Test.
- The primary objective of the study is to assess the performance of the Infinium HD Test using banked DNA samples extracted from whole blood patient samples derived from the intended use population.
- The secondary objective of the study is to determine the background number of chromosomal abnormalities per person in the general population based on the resolution of the Infinium HD Test.
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29403
- Medical University of South Carolina
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77021
- Baylor College of Medicine
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84108
- ARUP Laboratories
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Method Comparison - Sample Inclusion Criteria
The following are criteria for inclusion of extracted genomic DNA samples in the method comparison sample pool:
- Sample is from a patient referred for post-natal cytogenetic testing.
- Sample gender is known.
- Sample quantity available for testing is ≥ 1 microgram of genomic DNA at a concentration of 60-80 nanograms per microliter (60-80ng/µl).
- Sample is extracted genomic DNA from EDTA or heparin-anticoagulated whole blood.
- Sample has been stored at 2 to 8°C or -15 to -25°C for no greater than three years from the date of extraction.
- Sample has been tested by a reference method. Acceptable reference methods include karyotype, FISH, qPCR, MLPA, and methylation analysis.
Method Comparison - Sample Exclusion Criteria
- Sample is from a patient not referred for post-natal cytogenetic testing.
- Sample is from a patient referred for cytogenetic oncology testing.
- Sample quantity < 1 microgram of genomic DNA or less than 60 nanograms per microliter (60ng/µl).
- Sample was improperly stored or was extracted from a sample that was improperly stored.
- Sample was tested by an Illumina array during standard of care testing.
Clinical Specificity - Sample Inclusion Criteria
The following are criteria for inclusion of extracted genomic DNA samples in the clinical specificity sample pool:
- Sample gender is known.
- Sample is from a patient not referred for post-natal cytogenetic testing.
- Sample quantity available for testing is ≥ 1 microgram of genomic DNA at a concentration of at least 60-80 nanograms per microliter (60-80ng/µl).
- Sample is extracted genomic DNA from EDTA or heparin-anticoagulated whole blood.
- Sample has been stored at 2 to 8°C or -15 to -25°C for no greater than three years from the date of extraction.
Clinical Specificity - Sample Exclusion Criteria
- Sample is from a patient referred for post-natal cytogenetic testing.
- Sample quantity < 1 microgram of genomic DNA or less than 60 nanograms per microliter (60ng/µl).
- Sample was improperly stored or was extracted from a sample that was improperly stored.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: Case-Alleen
- Tijdsperspectieven: Retrospectief
Cohorten en interventies
Groep / Cohort |
|---|
|
Method Comparison Group
The method comparison group will consist of de-identified, leftover DNA samples from patients referred for post-natal cytogenetic testing.
|
|
Clinical Specificity Group
The clinical specificity group will consist of de-identified, leftover DNA samples from non-phenotypic patients, or patients not referred for post-natal cytogenetic testing.
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- Cyto-001
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .